Stevens–Johnson Syndrome and Chronic Ocular Surface Damage
Stevens–Johnson syndrome is a severe mucocutaneous reaction. It often follows a drug exposure or infection. The acute phase can injure the skin, mouth, and eyes together. Ocular involvement is common and may persist long after the skin heals.
In the acute stage, inflammation attacks the eyelid margins, conjunctiva, and cornea. Membranes can form on the ocular surface. Then the tear-producing structures may fail. Goblet cells can disappear. As a result, the eye loses both watery tears and stable mucus.
Chronic damage follows this early injury. The ocular surface becomes dry, scarred, and poorly wettable. Lashes may turn inward and rub the cornea. The conjunctiva can shrink and restrict eye movement. Symblepharon may tether the eyelid to the globe.
The cornea is especially vulnerable. Persistent epithelial defects can appear. Vascularization and scarring may reduce vision. Secondary infection can worsen the loss. In severe cases, the ocular surface becomes keratinized.
Drug associations remain important. Certain antibiotics, anticonvulsants, and anti-gout medicines have been linked to the syndrome. Still, not every exposure causes disease. Genetic risk and immune response also matter.
Early eye care can limit later disability.
Lubrication protects the surface. Removal of membranes may reduce scarring. Amniotic membrane can cover inflamed tissue. Lid hygiene and control of inflammation also help. Even so, some patients develop lasting dryness and pain.
Long-term management is staged. Preservative-free tears support comfort. Punctal occlusion may conserve residual tears. Scleral lenses can vault the cornea and bathe it in fluid. In advanced disease, surgeons may reconstruct the lids and fornices. Keratoprosthesis is reserved for selected end-stage cases.
Vision loss is not the only burden. Photophobia, chronic pain, and poor blinking affect daily life. Therefore, rehabilitation should include low-vision support and counseling. Regular follow-up remains essential because the surface can decompensate after a quiet period.
Research continues to refine care.
Better acute protocols may reduce chronic sequelae. Biomarkers could identify patients at highest ocular risk. Comparative studies of mucous-membrane grafts, lids surgery, and prosthetic replacement of the ocular surface also matter.
Stevens–Johnson syndrome can convert a short systemic illness into lifelong ocular disease. Prompt recognition of eye involvement is critical. Sustained surface rehabilitation can then preserve comfort and remaining vision.